TAK:NYSE
Takeda Pharmaceutical Co Ltd
$19.68
arrow_downward
-0.08%(-0.015) 1D
Oct 19, 2:30:04 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TAK...
Open
$19.55
High
$19.80
Low
$19.55
Mkt. cap
63.14B
Avg. vol.
2.60M
Volume
1.50M
Dividend
3.20%
Quarterly dividend
$0.16
Ex-dividend date
Sep 29, 2026
52-wk high
$19.89
52-wk low
$12.99
EPS
-$0.33
Beta
-0.06
Shares outstanding
3.20B
No. of employees
47K
Open
$19.55
High
$19.80
Low
$19.55
Mkt. cap
63.14B
Avg. vol.
2.60M
Volume
1.50M
Dividend
3.20%
Quarterly dividend
$0.16
Ex-dividend date
Sep 29, 2026
52-wk high
$19.89
52-wk low
$12.99
EPS
-$0.33
Beta
-0.06
Shares outstanding
3.20B
No. of employees
47K
News stories
From web sources and news partners
marketscreener.com
·
2 hours ago
Takeda Pharmaceutical Company Limited Announces New Data From VERDICT Showing Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Prolongs Time To First Ulcerative Colitis-Related Complication
ad-hoc-news.de
·
4 hours ago
Takeda stock: Results are due October 29, 2026 for Takeda stock
Benzinga
·
5 hours ago
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
ad-hoc-news.de
·
10 hours ago
Takeda reports positive TAK-881 data for Takeda Pharmaceutical stock
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47K
FoundedJun 12, 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Analyst ratings
Based on 1 analyst giving stock ratings to TAK in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for TAK in the last 3 months
Highest
Current $19.68
$43.06 (+118.82%)
Average
$43.06 (+118.80%)
Lowest
$43.06 (+118.82%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Koichi Mamegano Bank of America Securities | Buy | Maintained | ¥6,800.00 | +34,452.8% | 09/14/2026 |
Michael Nedelcovych TD Cowen | Buy | Maintained | $21.00 | +6.7% | 06/04/2026 |
Next call in 10 days
Thu, Oct 29, 12:00 PM
Fiscal period
Q2 2027
- Normalized EPS / Est. (JPY)
- GAAP EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
- / 1.15T
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in JPY | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.11T | 1.19T | 1.09T | 1.22T |
Cost of goods sold | 380.06B | 401.15B | 453.33B | 406.68B |
Cost of revenue | 380.06B | 401.15B | 453.33B | 406.68B |
Research and development expenses | 161.48B | 175.23B | 187.96B | 167.40B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 253.55B | 282.78B | 291.96B | 286.51B |
Operating expense | 562.57B | 661.30B | 519.65B | 612.60B |
Total operating expenses | 942.63B | 1.06T | 972.98B | 1.02T |
Operating income | 170.17B | 129.25B | 121.56B | 200.62B |
Other non operating income | 77.96B | -197.22B | 181.53B | -28.14B |
EBT including unusual items | 28.17B | 133.86B | -455.02B | 162.72B |
EBT excluding unusual items | 128.86B | 114.17B | 71.49B | 161.92B |
Income tax expense | 39.90B | 30.13B | -86.62B | 49.46B |
Effective tax rate | 141.64% | 22.51% | 19.04% | 30.40% |
Other operating expenses | 16.12B | 67.13B | -64.27B | 53.17B |
Net income | -11.80B | 103.64B | -368.47B | 113.20B |
Net profit margin | -1.06% | 8.70% | -33.66% | 9.28% |
Earnings per share | - | - | - | - |
Interest and investment income | 43.92B | 181.35B | - | 24.61B |
Interest expense | -161.10B | - | -239.63B | -35.70B |
Net interest expenses | -117.18B | 181.35B | -239.63B | -11.09B |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 355.15B | 319.89B | 192.73B | 363.66B |
Gain or loss from assets sale | 303.00M | 358.00M | 1.46B | -6.00B |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1